Status:
UNKNOWN
Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients
Lead Sponsor:
Sherief Abd-Elsalam
Conditions:
Diabetes
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
Evaluation of the glycemic efficacy of cabergoline on diabetic patients
Detailed Description
Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is a fundamental par...
Eligibility Criteria
Inclusion
- Diabetic patients.
Exclusion
- Other drugs administration
Key Trial Info
Start Date :
October 14 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03313661
Start Date
October 14 2017
End Date
December 1 2020
Last Update
August 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sherief Abd-Elsalam
Cairo, Egypt